New drug combo tested to shrink prostate cancer before surgery
NCT ID NCT07163910
Summary
This study is testing whether adding a drug called homoharringtonine to standard hormone-blocking therapy can better shrink prostate cancer before surgery. It aims to see if this combination leads to less cancer remaining after surgery and improves long-term results. The study is for men with aggressive or spreading prostate cancer who have not yet had treatment and plan to have surgery.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Zhongda Hospital
RECRUITINGNanjing, Jiangsu, 210009, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.